Effect of Mindfulness on Opioid Use and Anxiety During Primary Care Buprenorphine Treatment (R33 Phase)
NCT04278586 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 260
Last updated 2025-07-22
Summary
This will be a randomized controlled trial (RCT) designed to compare live-online Mindful Recovery Opioid Care Continuum (M-ROCC) groups with a live-online control group on the primary outcome of number of biochemically confirmed opioid negative abstinent periods (defined by a negative oral fluid test \[negative for opiate, oxycodone, fentanyl, methadone\] AND no self-reported illicit opioid use) during the final six two-week periods of the study (study weeks 13-24).
Conditions
- Opioid-use Disorder
- Stress Related Disorder
- Anxiety
- Pain Interference
Interventions
- BEHAVIORAL
-
Live-Online M-ROCC
1. LDM (Low-Dose Mindfulness): A 4-wk intro mindfulness program for OUD, 50-60 min/week including explicit training in use of mobile mindfulness apps, with rolling admission and ascending practice dose ladder. 2. MTPC (Mindfulness Training for Primary Care): An eight-week intensive mindfulness group with ascending practice dose ladder and skill integration over 16 weeks with 60 minutes/wk. 3. MCS (Mindfulness Maintenance Check-in Support): Ongoing weekly mindfulness group with check-in and reminders, leveraging mobile mindfulness apps and motivational counseling for graduates of LDM for 50-60 mins/wk. After completion of the LDM group, participation in various levels is fluid based on patient motivation, choice, and readiness.
- BEHAVIORAL
-
Live-Online Control
A time- and attention-matched live online control group. The manualized control intervention developed for the basic group-based opioid treatment group in primary care uses 16 core modules and 8 elective modules that are common to eclectic approach in treatment as usual addiction recovery groups (including engagement and group development activities with a mix of basic CBT skills, twelve-step facilitation, community reinforcement, and motivational interviewing). As an active group control, this method will help to isolate mindfulness as the putative mechanism of action by controlling for the therapeutic aspects of group without any reference to mindfulness.
Sponsors & Collaborators
-
National Center for Complementary and Integrative Health (NCCIH)
collaborator NIH -
Cambridge Health Alliance
lead OTHER
Principal Investigators
-
Zev Schuman-Olivier, MD · Study Principal Investigator
Study Design
- Allocation
- RANDOMIZED
- Purpose
- TREATMENT
- Masking
- SINGLE
- Model
- PARALLEL
Eligibility
- Min Age
- 18 Years
- Max Age
- 70 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2021-02-15
- Primary Completion
- 2023-09-19
- Completion
- 2023-09-19
Countries
- United States
Study Locations
More Related Trials
-
A Project to Test the Efficacy and Safety of An Innovative Treatment for Opiate Use Disorders.
NCT05995873 ·Status: UNKNOWN ·Phase: NA
-
Mindfulness-Based Relapse Prevention to Improve Medication Assisted Treatment Adherence and Drug-use Outcomes for Opioid Use Disorder
NCT05042388 ·Status: COMPLETED ·Phase: NA
-
A Study to Test Whether BI 1356225 Improves Impulsive Behavior in People With Opioid Use Disorder Who Are Taking Buprenorphine
NCT06628622 ·Status: SUSPENDED ·Phase: PHASE1
-
Mobile Medication Adherence Platform for Buprenorphine-Naloxone During Treatment of Opioid Use Disorder: Phase I Study
NCT04656899 ·Status: COMPLETED ·Phase: NA
-
Neurocognitive Mechanisms Underlying Smartphone-Assisted Prevention of Relapse in Opioid Use Disorder
NCT05336188 ·Status: ENROLLING_BY_INVITATION ·Phase: NA
-
Efficacy And Safety Of An Innovative Treatment Of Opiate Use Disorders
NCT04340622 ·Status: COMPLETED ·Phase: NA
-
Oral Buprenorphine as a Novel Low-dose Induction Strategy for Opioid Use Disorder
NCT06086275 ·Status: COMPLETED ·Phase: PHASE1
-
Determine the Safety of a Sublingual Tablet Formulation of Buprenorphine and Naloxone by Extending the Combination Tablet Availability to Physicians in Office-Based Practice
NCT00007527 ·Status: COMPLETED ·Phase: PHASE4
-
Biomarkers of Injectable Extended Release Naltrexone Treatment
NCT02324725 ·Status: COMPLETED ·Phase: PHASE4
-
Combined tDCS and Cognitive Training as an Adjunctive Treatment in Opioid Use Disorder
NCT07158853 ·Status: RECRUITING ·Phase: NA
-
Evaluating the Pharmacokinetics and Patient Outcomes of Buprenorphine Microdosing
NCT05307458 ·Status: UNKNOWN
-
A Trial of Directly Observed and Long-term Varenicline
NCT03365362 ·Status: COMPLETED ·Phase: PHASE4
-
Combining Neuro-Imaging and Non-Invasive Brain Stimulation for Clinical Intervention in Opioid Use Disorder
NCT04495673 ·Status: TERMINATED ·Phase: NA
-
Prescription Opioid Abuse Among Pain Patients: Predictors of Relapse
NCT01967641 ·Status: COMPLETED ·Phase: PHASE2
-
Cannabidiol Use to Reduce Cravings in Individuals With Opioid Use Disorder on Buprenorphine
NCT04192370 ·Status: COMPLETED ·Phase: PHASE2
-
Cannabidiol on Reward- and Stress-related Neurocognitive Processes in Individuals With Opioid Use Disorder
NCT04982029 ·Status: COMPLETED ·Phase: PHASE2
-
SUBLOCADE Long-term Outcomes
NCT05860959 ·Status: COMPLETED
-
Buprenorphine/Naloxone for Treatment of Opiate Dependence - 9
NCT00000344 ·Status: COMPLETED ·Phase: PHASE2
-
Phase 1 Study to Evaluate RDC-0313 Coadministered With Buprenorphine to Opioid-Experienced Healthy Adults
NCT01046539 ·Status: COMPLETED ·Phase: PHASE1
-
Treatment Seeking Participants With Opioid Use Disorders Assessing Tolerability of Depot Injections of Buprenorphine
NCT02357901 ·Status: COMPLETED ·Phase: PHASE3
-
Examining the Role of the Orexin System in Sleep and Stress in Persons With Opioid Use Disorder
NCT04287062 ·Status: COMPLETED ·Phase: PHASE2
-
Safety and Preliminary Efficacy of ANS-6637 to Reduce Drug Craving and Harm in People With Opioid Use Disorder
NCT04169360 ·Status: WITHDRAWN ·Phase: PHASE2
-
Injectable Buprenorphine in Prison: A Preference Trial
NCT06880718 ·Status: RECRUITING ·Phase: PHASE4
-
Pupillary Unrest in Ambient Light, and Relationship to Opioid-Induced Respiratory Depression
NCT04301895 ·Status: COMPLETED ·Phase: PHASE1
-
PRimary Care Opioid Use Disorders Treatment (PROUD) Trial
NCT03407638 ·Status: COMPLETED ·Phase: NA